source
- Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trialSellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
- Medtronic to acquire Contego Medical for over $380 million to expand carotid and peripheral vascular portfolioMedtronic announced it will purchase Contego Medical, a developer of carotid artery disease and peripheral thrombectomy technologies. The deal is valued at more than $380 million, with potential a…